N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia

American Journal of Psychiatry

Volumn 158, Issue 9, 2001, Pages 1400-1410

  Dracheva, S ^a   Marras, S A E ^a   Elhakem, S L ^a   Kramer, F R ^a   Davis, K L ^a   Haroutunian, V ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLUTAMIC ACID DERIVATIVE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; RECEPTOR SUBUNIT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; GENE EXPRESSION; GERIATRIC PATIENT; HUMAN; MALE; NEUROPATHOLOGY; NEUROPSYCHIATRY; OCCIPITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

ACTINS; AGED; ALZHEIMER DISEASE; ANIMALS; GENE EXPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; OCCIPITAL LOBE; PREFRONTAL CORTEX; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0034843740     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.9.1400     Document Type: Article

References (96)

1. Emerging principles of altered neural circuitry in schizophrenia
2. Glutamatergic aspects of schizophrenia
3. A glutamatergic deficiency model of schizophrenia
4. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
5. The role of serotonin in schizophrenia
6. New developments in dopamine and schizophrenia
7. Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer's-type dementia
8. Schizophrenia and glutamatergic transmission
9. Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia
10. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, IV: Further evidence for regional and behavioral specificity
11. Quantitative shape analysis of the temporal and prefrontal lobes of schizophrenic patients: A magnetic resonance image study
12. Neuropathology of schizophrenia
13. The neuropathology of schizophrenia: A critical review of the data and their interpretation
14. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum
15. Cell biology of the hippocampal formation in schizophrenia
16. A qualitative and quantitative analysis of the entorhinal cortex in schizophrenia
17. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
18. Altered expression of NMDA receptor-associated post-synaptic density proteins in the thalamus in schizophrenia
19. The limbic cortex in schizophrenia: Focus on the anterior cingulate
20. Recent advances in the phencyclidine model of schizophrenia
21. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses
22. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders
23. Glutamate, dopamine, the frontal cortex, and schizophrenia
24. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
25. The phencyclidine-glutamate model of schizophrenia
26. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
27. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
28. Glutamate receptor dysfunction and schizophrenia
29. Neurotransmitter interactions in schizophrenia - Therapeutic implications
30. 3H] kainic acid binding in the prefrontal cortex in schizophrenia
31. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients
32. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
33. A receptor subunit genes
34. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia
35. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia
36. Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia
37. NMDA receptor dysregulation in schizophrenic prefrontal cortex
38. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
39. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients
40. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
41. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
42. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia
43. Alterations in phencyclidine and sigma binding sites in schizophrenia brains: Effects of disease process and neuroleptic medication
44. Cognitive deficit in schizophrenia and its neurochemical basis
45. Pharmacological animal models of dementia
46. NMDA receptor hypofunction model of schizophrenia
47. N-methyl-D-aspartate receptor mediated toxicity in nonneuronal cell lines: Characterization using fluorescent measures of cell viability and reactive oxygen species production
48. Excitatory amino acid agonists and antagonists: Pharmacology and therapeutic applications
49. Cloned glutamate receptors
50. Human brain receptors, VIII: The distribution of ionotropic glutamate receptors in the human hippocampus (image)
51. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: Organizational features related to cortical circuitry, function and disease
52. Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain
53. NMDA and AMPA receptors on neocortical neurons are differentially distributed
54. Neuronal and glial localization of NMDA receptors in the cerebral cortex
55. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain
56. Glutamate receptors in cortical plasticity: Molecular and cellular biology
57. Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits
58. Pharmacological characterization of heterodimeric NMDA receptors composed of NR 1a and 2B subunits: Differences with receptors formed from NR 1a and 2A
59. Glutamate receptor expression in schizophrenic brain
60. The postsynaptic density at glutamatergic synapses
61. Synapse structure: Glutamate receptors connected by the shanks
62. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95
63. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain
64. Pathophysiological implications of the structural organization of the excitatory synapse
65. Glutamate receptor anchoring proteins and the molecular organization of excitatory synapses
66. PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses
67. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein
68. The subcellular distribution of nitric oxide synthase relative to the NR1 subunit of NMDA receptors in the cerebral cortex
69. Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein
70. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients
71. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites
72. Convergence of cognitive and adaptive decline in late-life schizophrenia
73. Alzheimer's disease and related neurodegenerative diseases in elderly schizophrenic patients
74. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: Standardization of the neuropathologic assessment of Alzheimer's disease
75. Cholinergic markers are not decreased in early Alzheimer's disease
76. Regional distribution of neuritic plaques in nondemented elderly and cases of very mild Alzheimer's disease
77. Cytoarchitectonic definition of prefrontal areas in the normal human cortex, 1: Remapping of areas 9 and 46 using quantitative criteria
78. Local circuit neurons of the prefrontal cortex in schizophrenia: Selective increase in the density of calbindin-immunoreactive neurons
79. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
80. Multiplex detection of four pathogenic retroviruses using molecular beacons
81. Thermodynamic basis of the enhanced specificity of structured DNA probes
82. Multiplex detection of single-nucleotide variations using molecular beacons
83. Molecular beacons: Probes that fluoresce upon hybridization
84. Kinetic PCR analysis: Real-time monitoring of DNA amplification reactions
85. Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression
86. Glutamate receptors in the mammalian central nervous system
87. Effects of post-mortem delay on subunits of ionotropic glutamate receptors in human brain
88. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats
89. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics
90. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: Regulation by haloperidol
91. N-methyl-D-aspartate receptors: Different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents
92. Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo
93. C-Terminal truncation of NR2A subunits impairs synaptic but not extrasynaptic localization of NMDA receptors
94. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain
95. Localization of NMDA receptors in the cerebral cortex: A schematic overview